next generation semaglutide Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine Designing Next-Generation Cardiometabolic Outcome Trials

Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M et al

PMID 8039723

This test, available as a $99 add-on after your first month of treatment, reveals whether your genetics predispose you to rapid weight regain, allowing you and your provider to proactively plan for sustained therapy rather than cycling on and off medication

& Uehara, M

But when losing weight, some degree of muscle loss is to be expected

AHIP pledges to standardize ePA by 2027 took effect January 1, 2026 ( [15] ), and the CMS-0057-F rule mandates FHIR-based PA APIs by January 2027 ( [16] ), meaning even currently disconnected payers will be required to deploy compatible systems